After advancing its proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, bococizumab, into a global phase III development program that included six lipid-lowering and two cardiovascular (CVD) outcome trials (CVOTs), Pfizer Inc. blinked.